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Abstract
Genetic factors play an important role in the etiology of breast cancer. We carried out a multi-stage genome-wide
association (GWA) study in over 28,000 cases and controls recruited from 12 studies conducted in Asian and European
American women to identify genetic susceptibility loci for breast cancer. After analyzing 684,457 SNPs in 2,073 cases and
2,084 controls in Chinese women, we evaluated 53 SNPs for fast-track replication in an independent set of 4,425 cases and
1,915 controls of Chinese origin. Four replicated SNPs were further investigated in an independent set of 6,173 cases and
6,340 controls from seven other studies conducted in Asian women. SNP rs4784227 was consistently associated with breast
cancer risk across all studies with adjusted odds ratios (95% confidence intervals) of 1.25 (1.2021.31) per allele
(P= 3.2610225) in the pooled analysis of samples from all Asian samples. This SNP was also associated with breast cancer
risk among European Americans (per allele OR = 1.19, 95% CI = 1.0921.31, P= 1.361024, 2,797 cases and 2,662 controls).
SNP rs4784227 is located at 16q12.1, a region identified previously for breast cancer risk among Europeans. The association
of this SNP with breast cancer risk remained highly statistically significant in Asians after adjusting for previously-reported
SNPs in this region. In vitro experiments using both luciferase reporter and electrophoretic mobility shift assays
demonstrated functional significance of this SNP. These results provide strong evidence implicating rs4784227 as a
functional causal variant for breast cancer in the locus 16q12.1 and demonstrate the utility of conducting genetic
association studies in populations with different genetic architectures.
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Introduction
Breast cancer is the most common malignancy among women
in the United States and many other parts of the world. Genetic
factors play an important role in the etiology of breast cancer.
Only a very small fraction of cases in the general population,
however, can be explained by high-penetrance breast cancer
susceptibility genes, such as BRCA1 and BRCA2. Recent genome-
wide association (GWA) studies [1–8], including our own study
among Chinese women in Shanghai [6], have identified multiple
common genetic susceptibility loci for breast cancer. Each of the
common genetic factors identified thus far confer only a small to
moderate risk for breast cancer. With the exception of our study,
all other reported GWA studies have been conducted among
women of European ancestry. GWA studies conducted in other
populations could identify not only additional novel genetic
variants for breast cancer but also help to fine map causal variants
for regions reported from previous GWA studies.
In early 2009, we reported a novel genetic susceptibility locus at
6q25.1 for breast cancer risk in a fast-track replication of promising
SNPs selected from a GWA scan of 1,505 cases and 1,522 controls
recruited in the Shanghai Breast Cancer Study (SBCS) [6]. We have
since increased the sample size for the initial GWA scan to 2,073
cases and 2,084 controls to increase the statistical power to identify
novel genetic risk variants for breast cancer. We have recently
completed the second fast-track replication using data and
biological samples collected from 13,395 cases and 10,917 controls
recruited in 12 studies of Asian and European ancestry. SNP
rs4784227, located at 16q12.1, a region identified from a previous
GWA study conducted in Europeans [1,3], was found to be a risk
variant for breast cancer in Asian women independent of SNPs
reported from the previous study [1,3]. In vitro experimental results
provide strong support for the functional significance of this SNP
and suggest that this SNP may explain the association observed for
breast cancer in this locus. Herein, we report findings from this large
genetic study of breast cancer.
Methods
Ethics statement
Approval was granted from relevant review boards in all study
sites; all included subjects gave informed consent.
Study population
Included in this consortium project were 15,468 cases and
13,001 controls from 12 studies (Table 1). Detailed descriptions of
these participating studies and demographic characteristics of
study participants are provided in the supplement Text S1 and
Table S1. Briefly, the consortium included 19,796 Chinese women
from seven studies conducted in Shanghai [6,9] (three studies,
n = 10,497), Tianjin [10] (n = 3,115), Nanjing [11,12] (n = 2,885),
Taiwan [13] (n = 2,131), and Hong Kong [14] (n = 1,168); 3,214
Japanese women from three studies conducted in Hawaii [15]
(n = 1,120), Nagoya [16] (n = 1,288), and Nagano (n= 806) [17];
and 5,459 European Americans from the Nashville Breast Health
Study (NBHS, n= 3,172) and the Nurses’ Health Study (NHS,
n= 2,287, included as part of the Cancer Genetic Markers of
Susceptibility Project - CGEMS). All cases and controls recruited
in the Shanghai studies were included in Stages I and II, and
subjects from the remaining Asian studies were included in Stage
III. Data from CGEMS were used for help to select SNPs for
Stage II. Cases and controls recruited in NBHS and the NHS
(CGEMS) were included in the final stage to evaluate the
generalizability of the findings.
Genotyping and quality control procedures
Genotyping for Stage I has been described previously [6].
Briefly, the initial 300 subjects were genotyped using the
Affymetrix GeneChip Mapping 500 K Array Set and the
remaining 3,918 subjects were genotyped using the Affymetrix
Genome-Wide Human SNP Array 6.0. We included one negative
control and three positive quality control (QC) samples from the
Coriell Cell Repositories (http://ccr.coriell.org/) in each of the 96-
well plates for Affymetrix SNP Array 6.0 genotyping. A total of
127 positive QC samples were successfully genotyped and the
average concordance rate was 99.9% with a median value of
100%. The sex of all study samples was confirmed to be female.
The identity-by-descent analysis based on identity-by-state was
conducted to detect first-degree cryptic relationships using
PLINK, version 1.06. All samples with a call rate ,95% were
excluded. The SNPs were excluded if: (i) minor allele frequency
(MAF) ,1%, (ii) call rate ,95%, or (iii) genotyping concordance
rate ,95% in quality control samples. The final dataset included
2,073 cases and 2,084 controls for 684,457 markers.
Genotyping for Stage II was completed using the iPLEX
Sequenom MassArray platform. Included in each 96-well plate as
QC samples were two negative controls (water), two blinded
Table 1. Characteristics of study participants and number of
SNPs analyzed in each stage.
Cases Controls
Study population N Agec N Age
Stage I (684,457 SNPs)a
Shanghai – SBCS (Chinese) 2,073 49.368.3 2,084 49.468.5
Stage II (53 SNPs)
Stage II total 4,425 53.9610.2 1,915 52.869.2
Shanghai -SBCS (Chinese) 972 50.468.3 1,001 50.969.3
Shanghai - SBCSS (Chinese) 3,453 54.9610.5
Shanghai - SECS (Chinese) 914 54.968.5
Stage III (4 SNPs)b
Stage III total 6,173 52.6611.5 6,340 51.2610.9
Tianjin (Chinese) 1,532 51.7611.4 1,583 51.9610.5
Nanjing (Chinese) 1,446 51.5611.4 1,439 51.3611.2
Taiwan (Chinese) 1,066 51.5610.7 1,065 47.5610.1
Hong Kong (Chinese) 517 45.869.5 651 45.6610.3
Nagoya - Japan (Japanese) 644 51.4611.0 644 51.1610.9
Nagano - Japan (Japanese) 403 53.7610.5 403 53.9610.2
Hawaii - MEC (Japanese) 565 65.268.4 555 60.468.4
European Americans b
NBHS 1,652 54.9610.2 1,520 52.2611.0
CGEMS 1,145 1,142
Total 15,468 52.5610.7 13,001 51.2610.2
Chinese 11,059 51.8610.3 8,737 50.4610.1
Japanese 1,612 56.8611.8 1,602 55.0610.7
European Americans 2,797 2,662
a Selected from SNPs included in the Affymetrix 6.0 SNP array with MAF$1%,
call rate$95%, and QC consistency.
bWith the exception of studies in Nanjing (2 SNPs), Tianjin (3 SNPs) and Nagoya
Japan (1 SNP), NBHS (3 SNPs), CGEMS (2 SNPs genotyped and 2 SNPs imputed),
four SNPs were analyzed in all other studies.
c Mean 6 SD.
doi:10.1371/journal.pgen.1001002.t001
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duplicates, and two samples from the HapMap project. To
compare the consistency between the Affymetrix and Sequenom
platforms, we also included 124 samples from Stage I that were
genotyped by Affymetrix SNP 6.0. The mean concordance rate
was 99.7% for the blind duplicates, 98.8% for HapMap samples,
and 98.6% between Sequenom and Affymetrix 6.0 genotyping.
Genotyping for Stage III and NBHS was performed using
TaqMan at five different centers. The genotyping assay protocol
was developed and validated at the Vanderbilt Molecular
Epidemiology Laboratory, and TaqMan genotyping assay re-
agents were provided to investigators from the Tianjin study
(Tianjin Cancer Institute and Hospital), Nanjing study (Nanjing
Medical University), Multiethnic Cohort Study (MEC, University
of Southern California), and Nagano Breast Cancer study (Japan
National Cancer Center), who conducted the genotyping assays at
their own laboratories. Samples from the four other studies (Hong
Kong, Taiwan, Nagoya, and Nashville) were genotyped at the
Vanderbilt Molecular Epidemiology Laboratory. During the
genotyping, two negative controls were included in each 96-well
plate, along with 30 unrelated European and 45 Chinese samples
from the HapMap project genotyped together with each study for
QC purposes. The consistency rate was 100.0% for the HapMap
samples comparing genotyping data obtained from the current
study with data obtained in the HapMap project. Each of the non-
Vanderbilt laboratories was asked to genotype a trial plate
containing DNA from 70 Chinese samples before genotyping
study samples. The consistency rate across all centers for these trial
samples was 100% compared with genotypes previously deter-
mined at Vanderbilt. In addition, replicate samples comparing 3–
7% of all study samples were dispersed among the genotyping
plates at all centers.
Plasmid constructs and luciferase reporter assays
A 3.0 kb DNA fragment containing major allele (C) of
rs4784227 was PCR amplified by using forward primer 59-
GATCAGCTAGCCATAGTGTGGTAGCTAGTTG-39 and
backward primer 59-GATCA CTCGAGCTGCTGGGCT-
TAGCTACAAG-39. This fragment was subcloned into luciferase
reporter vector, pGL3 basic, pGL3 promoter, and pGL3 enhancer
(Promega, WI) between Nhe1 and Xho1 restriction sites, respec-
tively. The minor allele (T) sequence was generated by using
QuickChange Site-Directed Mutagenesis Kit (Strategene, La Jolla,
CA) with the following pair of oligonucleotides, 59- GAGTATT-
TACATCACAATAATCAGCAAACACTACAAATTGGGAC-
39 and 59- GTCCCAATTTGTAGTGTTTGCTGATTATTGT-
GATGTAAATACTC-39. All DNA constructs were verified by
sequencing analyses. Transfection was performed with the use of
FuGene 6 Transfection Reagent (Roche Diagnostics, Indianapolis,
IN) in triplicate for each of the constructs. Briefly, 1226105 cells
of HEK 293, MCF-7, MCF10A, and MDA-231 cells were seeded
in 24-well plates and co-transfected with pGL4.73, a Renilla
expressing vector which served as a reference for transfection
efficiency. Thirty-six to 48 hours later the cells were lysed with
Passive Lysis Buffer, and luminescence (relative light units) was
measured using the Dual-Luciferase Assay System (Promega, WI).
The rs4784227 regulatory activity was measured as a ratio of
firefly luciferase activity to renilla luciferase activity, and the mean
from four independent experiments are presented.
Electrophoretic mobility shift assay
Biotin-labeled, double stranded oligonucleotide probes 59-
ATTTGTAGTGTTTGCCGATTATTGTGATGT-39 and 59-
ACATCACAATAATCGGCAAACACTACAAAT-39, and 59-A-
TTTGTAGTGTTTGCTGATTATTGTGATGT-39and 59- A-
CATCACAATAATCAGCAAACACTACAAAT-39 containing
the major and minor allele sequence of rs4784227 were
synthesized. The probes were incubated with nuclear protein
extracts from MCF10A, MCF7, and MDA-MB-231 cells, in the
presence or absence of competitors, i.e. unlabelled probes. Protein-
DNA complexes were resolved by polyacrylamide gel electropho-
resis and detected using a LightShift Chemiluminescent EMSA kit
(Pierce Biotechnology, Rockford, IL).
Statistical analyses
In Stage I, PLINK version 1.06 was used to analyze genome-
wide data. Population structure was investigated by using the
principal component analysis implemented in EIGENSTRAT
[18] (http://genepath.med.harvard.edu/,reich/Software.htm). A
set of 12,533 SNPs with MAF$5% in Chinese and a distance
$25 kb between two adjacent SNPs was selected to evaluate the
population structure. The first two principal components were
included in logistic regression models for adjustment of population
structures. Odds ratios (OR) and 95% confidence intervals (CIs)
were estimated by logistic regression analysis. ORs were also
estimated for the variant allele based on a log-additive model. Age
was adjusted for in the analyses of Stages I and II data. In Stage
III, individual data were obtained from each study for a pooled
analysis. ORs from multiple studies were adjusted for age and
study site. Heterogeneity across studies and between ethnicities
was assessed with likelihood ratio tests. Stratified analyses by
ethnicity, menopausal status, and estrogen receptor (ER) status
were carried out. P-values based on 2-tailed tests are presented.
Individual genotyping data from the Cancer Genetic Markers of
Susceptibility (CGEMS, http://cgems.cancer.gov/data/) study
were obtained through an approved data request application in
order to perform meta-analyses of GWA scan data from both the
Shanghai studies and the CGEMS project. Program MACH
(http://www.sph.umich.edu/csg/abecasis/MACH/) was used for
genotype imputation that determines the probability distribution
of missing genotypes conditional on a set of known haplotypes
while simultaneously estimating the fine-scale recombination map.
For the Shanghai studies, imputation was based on 660,118
autosomal SNPs genotyped in Stage I that had a MAF.1% and
passed the QC procedure, using the phased Asian data from
HapMap Phase II (release 22) as the reference. A total of
2,272,352 SNPs showed an imputation quality score $0.90. The
CGEMS GWA scan data were genotyped using Illumina
Author Summary
Breast cancer is one of the most common malignancies
among women worldwide. Genetic factors play an
important role in the etiology of breast cancer. To identify
genetic susceptibility loci for breast cancer, we performed
a genome-wide association study in 15,468 breast cancer
cases and 13,001 controls. A single nucleotide polymor-
phism (SNP) rs4784227 located on chromosome 16q12.1, a
previously-reported region for breast cancer risk, was
found to be associated with breast cancer risk. The
association of this SNP with breast cancer risk remained
highly significant in Asians after adjusting all previously-
reported SNPs in this region. In vitro biochemical
experiments using both luciferase reporter and electro-
phoretic mobility shift assays confirmed the functional
importance of this SNP. Our results demonstrate the
importance of conducting genetic association studies in
populations with different genetic backgrounds to identify
functional variants.
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HumanHap550 for 1,142 breast cancer cases and 1,145 controls
nested within the Nurses’ Health Study cohort. For CGEMS,
genotypes were imputed based on 513,602 autosomal SNPs with
MAF.1%, using phased CEU data from HapMap Phase II
(release 22) as the reference. A total of 2,168,847 SNPs showed an
imputation quality score $0.90. To evaluate associations between
imputed SNP data and breast cancer risk, logistic regression
(additive model) was used, in which SNPs were represented by the
expected allele count, an approach that takes into account the
degree of uncertainty in the genotype imputation.
Meta-analyses of GWA scan data for SBCS and CGEMS were
conducted for 1,968,549 SNPs with a MAF $1% in both
populations and imputation quality scores $0.90. Meta-analyses
were performed using a weighted z-statistics method, where
weights were proportional to the square root of the number of
individuals in each sample and standardized such that the weights
added up to one. The z-statistic summarizes the magnitude and
direction of the effect relative to the reference allele. An overall z-
statistic and p value were then calculated from the weighted
average of the individual statistics. Calculations were implem-
ented in the METAL package (http://www.sph.umich.edu/csg/
abecasis/Metal).
SNP selection for validation in Stage II. In the present
study, we selected 59 promising SNPs for fast-track replication in
Stage II, including 4,425 cases and 1,915 controls recruited in the
Shanghai studies. Only SNPs included in the Affymetrix 6.0 SNP
arrays were selected for Stage II evaluation. Selection criteria for
these SNPs were: (i) MAF$5%, (ii) very clear genotyping clusters,
(iii) not in strong LD (r2#0.5) with any of the previously confirmed
breast cancer genetic risk variants in CHB/JPT, (iv) consistent
with HWE with P.0.01 in controls, (v) P,0.001 in the meta-
analyses of CGEMS and SBCS GWA scan data for SNPs on
Affymetrix 6.0 array, having the same direction of association in
both studies, and P#0.01 for SBCS GWA scan data.
Results
Of the 53 successfully genotyped SNPs in Stage II (Table S2),
highly significant associations with breast cancer risk were found
for rs4784227 (16q12.1) with OR (95% CI) of 1.23 (1.16–1.31)
per T allele (P for trend, 1.361028) (Table 2). Three other SNPs
also showed a significant or marginally significant association
with breast cancer risk. These four SNPs were selected for further
validation in Stage III, which included 6,173 cases and 6,340
controls of Asian ancestry from seven studies in the Asia Breast
Cancer Consortium (Methods; Table S1). SNP rs4784227 was
consistently associated with breast cancer risk in all studies
(Figure 1), with an OR of 1.25 (95% CI: 1.20–1.31,
P=3.2610225) in the pooled analysis of Asian samples from all
three stages. No heterogeneity in the association of this SNP with
breast cancer was observed across the studies included in the
consortium. The association of rs4784227 with breast cancer risk
was observed in both pre-menopausal (OR: 1.24 (1.17–1.32) and
P=6.5610212), and post-menopausal women (OR: 1.27 (1.19–
1.35) and P=3.0610214) (data not shown in tables). The positive
association was stronger in ER(+) breast cancer (per allele OR
= 1.29, 95% CI= 1.23–1.36, P=3.0610223) than in ER(2)
breast cancer (per allele OR =1.19, 95% CI= 1.12–1.26,
P=1.361028). In case-only analyses, when compared with cases
with ER(2) cancer, ORs associated with ER(+) breast cancer
Table 2. Results from Stages I to III for rs4784227 and Stages I and II for other three SNPs that showed promising associations with
breast cancer risk in Stage II.
OR(95%CI)c
SNP (chr) Allelea Stage
No of
cases
No of
controls Frequencyb Heter Homo Per allele P for trend
rs10479046
(5q31.1)
C/T I 2,071 2,083 0.73/0.70 1.22(0.96–1.55) 1.42(1.12–1.80) 1.18(1.07–1.30) 7.261024
II 4,320 1,854 0.71/0.70 1.07(0.87–1.30) 1.15(0.94–1.40) 1.07(0.99–1.17) 0.10
I & II 6,391 3,937 0.72/0.70 1.09(0.94–1.27) 1.22(1.06–1.42) 1.11(1.05–1.18) 7.561024
rs3829849
(9q33.3)
T/C I 2,067 2,081 0.11/0.09 1.31(1.12–1.54) 1.15(0.66–1.99) 1.25(1.08–1.44) 0.002
II 4,331 1,871 0.10/0.09 1.19(1.03–1.38) 2.10(1.06–4.18) 1.23(1.08–1.41) 0.003
I & II 6,398 3,952 0.11/0.09 1.24(1.11–1.38) 1.34(0.89–2.01) 1.22(1.11–1.34) 4.461025
rs7966820
(12q24.1)
T/C I 2,063 2,074 0.15/0.13 1.28(1.10–1.48) 1.33(0.86–2.05) 1.24(1.09–1.40) 7.861024
II 4,351 1,856 0.15/0.14 1.00(0.88–1.14) 2.00(1.28–3.12) 1.10(0.98–1.23) 0.10
I & II 6,414 3,930 0.15/0.13 1.12(1.02–1.23) 1.60(1.19–2.16) 1.16(1.07–1.26) 4.061024
rs4784227
(16q12.1)
T/C I 2,066 2,078 0.29/0.25 1.18(1.04–1.34) 1.43(1.13–1.82) 1.19(1.08–1.31) 4.261024
II 4,280 1,843 0.28/0.23 1.32(1.18–1.48) 1.62(1.29–2.05) 1.30(1.19–1.42) 1.361028
I & II 6,346 3,921 0.28/0.24 1.24(1.14–1.35) 1.50(1.28–1.77) 1.23(1.16–1.31) 2.1610210
I, II & IIId 12,336 10,140 0.29/0.24 1.28(1.21–1.35) 1.52(1.37–1.69) 1.25(1.20–1.31) 3.2610225
a Risk allele/reference allele.
b Risk allele frequency in cases/controls.
c In Stage I, adjusted for age and the first two principal components for population structure, in Stage II adjusted for age.
d SNP rs4784227 was replicated in Stage III, and combined results from all three stages are presented.
doi:10.1371/journal.pgen.1001002.t002
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were found to be 1.09 (95% CI: 1.03–1.16; P for trend,
5.861023). None of the other three SNPs that showed a
significant association in Stage II, however, were replicated in
Stage III (Table S3).
SNP rs4784227 is located in 16q12.1, a region where three
genetic risk variants for breast cancer (rs8051542, rs12443621, and
rs3803662) were reported previously in a study conducted among
women of European ancestry [1]. Of these three previously
reported SNPs, the closest (rs3803662) is approximately 12.8 Kb
away from rs4784227. The linkage disequilibrium (LD) pattern of
this region in Asians is very different from the pattern found in
European descendents (Figure 2 and Table 3). In Stage I and II
samples, SNP rs4784227 is in low LD with previously-reported
SNPs, with r2 being 0.07, 0.14, and 0.37 for rs12443621,
rs3803662, and rs8051542, respectively (Table 3). In European
Americans included in the HapMap project, however, SNP
rs4784227 is in strong LD with SNP rs3803662 (r2 = 0.86) but
weakly correlates with the other two SNPs. SNPs rs8051542 and
rs3803662 each showed a significant association with breast cancer
risk (P=2.061023 and P=1.761024) in a combined analysis of
data from Stages I and II (Table 4). However, after adjusting for
rs4784227 the association with rs8051542 disappeared. Although
the positive association with rs3803662 remained, it was of only
borderline significance (P=0.12). SNP rs12443621, however,
showed no association with breast cancer risk, which is consistent
with results reported by the initial study of Asian women [1]. The
association of rs4784227 with breast cancer risk remained highly
significant after adjusting for these three previously-reported
SNPs, individually or in combination (Table 4). Haplotype
analyses of these four SNPs showed that all haplotypes containing
the T allele of rs4784227 were associated with an increased risk of
breast cancer, although not all point estimates were statistically
significant at P,0.05 due to a small sample size for several
haplotypes (Table S4).
In studies conducted in European Americans, SNP rs4784227
also showed a significant association with a per allele OR (95%
CI) of 1.17 (1.03–1.34) in CGEMS and 1.21 (1.07–1.37) in
NBHS (Table 5). A significant (NBHS) or marginally significant
(CGEMS) association was observed for rs3803662, a previously
reported SNP, but not for two other previously-reported SNPs.
After adjusting for rs4784227, no association with rs3803662 was
seen. On the other hand, the positive association with rs4784227
Figure 1. Per-allele OR for rs4784227 in association with breast cancer risk by study and ethnic groups.
doi:10.1371/journal.pgen.1001002.g001
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remained after adjusting for rs3803662 or the other two SNPs,
although the association was no longer statistically significant at
P,0.05.
To evaluate whether SNP rs4784227 has any intrinsic
regulatory function, we conducted an in vitro luciferase assay in
four cell lines including metastatic breast cancer cell MDA231,
non-metastatic breast cancer cell MCF-7, breast epithelial cell
MCF10A, and HEK293. Luciferase reporter constructs containing
a 3 kb DNA fragment with the reference allele C and the risk allele
T of rs4784227, respectively, were generated and transiently
transfected into these cells. By comparing to the respective empty
vectors, no luciferase activity change was observed in pGL3 basic
and pGL3 enhancer vectors that harbor rs4784227 fragments,
which indicate that rs4784227 fragments do not have intrinsic
promoter activity (data not shown). In contrast, in the pGL3
promoter vector, fragments containing rs4784227 reduced lucif-
erase activity, and the reduction was more apparent in fragments
containing risk allele T than the reference allele C (Figure 3A).
With the exception of the MCF7 cells, the difference between the
T and C allele was statistically significant at P#0.05.
To investigate whether the DNA sequence containing
rs4784227 may interact with nuclear proteins and if so, whether
a single nucleotide change in the rs4784227 site may alter the
protein-DNA interactions, we performed electrophoretic mobility
shift assays. In these assays, oligonucleotide probes corresponding
to the reference allele C or the risk allele T were incubated with
nuclear protein extracts from MCF10A, MCF-7, and MDA-231
cells. Compared with reference allele C, risk allele T in rs4784227
resulted in an altered DNA-protein complex intensity in these cells
(B and II) (Figure 3B). In contrast, risk allele T did not alter the
intensity of the nonspecific DNA-protein complex band (I). These
results were unaffected by the presence of large amounts of
unlabeled competitors.
Figure 2. SNP association at 16q12 with breast cancer risk. In SBCS (A) and CGEMS (B). Top panel: Results (-log10P) are shown for the
associations of breast cancer risk with directly genotyped (diamonds) and imputed (circles) SNPs located in the TOX3 and LOC643714 genes. P-values
for rs4784227 are shown in red for Stage I data and in blue for the combined data. The three previously-reported SNPs (rs8051542, rs12443621, and
rs3803662) are highlighted in black. Middle panel: Genomic view at 16q12.1. Gene locations are from the March 2006 UCSC genome browser
assembly. Bottom panel: Estimates of pairwise LD (r2) for common SNPs (with MAF$5%) from HapMap release 23a in the region from 10 kb
downstream of rs8051542 to 10 kb upstream of rs4784227.
doi:10.1371/journal.pgen.1001002.g002
Table 3. Linkage disequilibrium patterns among rs4784227
and the three previously-reported SNPs in 16q12.1.
SNPs rs8051542 rs12443621 rs3803662 rs4784227
Chinese rs8051542 0.1 0.08 0.37
rs12443621 0.77 0.04 0.07
rs3803662 0.81 0.25 0.14
rs4784227 0.76 0.52 0.87
Caucasians
rs8051542 0.01 0.13 0.12
rs12443621 0.13 0.3 0.3
rs3803662 0.52 0.92 0.86
rs4784227 0.54 1 1
D9: Lower left triangle.
r2: Upper right triangle.
Caucasians: European samples included in the HapMap project.
Chinese: subjects in Stages I and II.
doi:10.1371/journal.pgen.1001002.t003
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Discussion
In this multi-stage GWA study of over 15,486 cases and 13,001
controls, we identified SNP rs4784227 as highly significantly
associated with breast cancer in both Asians (per allele OR=1.25,
95% CI= 1.20–1.31, P=3.2610225) and European Americans
(per allele OR=1.19, 95% CI=1.09–1.31, P = 1.361024). SNP
rs4784227 is located at 16q12.1, a region reported previously to
harbor breast cancer genetic risk variants among European
descendents [1,3]. In Asians, however, this SNP is either not in
LD or only in weak LD with any of the three previously-reported
SNPs in these regions, and adjusting for these SNPs did not alter
the association of breast cancer with this newly-identified SNP.
Although in European Americans rs4784227 is in strong LD with
one of the previously-reported SNPs, rs3803602, the positive
association of rs4784227 with breast cancer remained after
adjusting for previously-reported SNPs. In vitro experiments
showed that risk allele T reduced luciferase activity and altered
DNA-protein binding patterns. These results implicate rs4784227
as a functional genetic risk variant for breast cancer, and this SNP
may explain, at least partially, the association of breast cancer with
other SNPs identified in 16q12.1.
SNP rs4784227 is located 18.4 kb upstream of the TOX3 gene
and in the evolutionarily-conserved region of intron of the
LOC643714 gene. Several transcription factors are predicted to
bind to this SNP (http://www.cbrc.jp/research/db/TFSEARCH.
html). This SNP, however, has not been shown to be in the coding
region for any non-coding RNA or miRNA/snoRNA/scaRNA
based on UCSC Genome Browser. Our luciferase reporter assays
showed that the intronic region harboring rs4784227 may have
Table 4. Association of rs4784227 and the three previously-reported SNPs at 16q12with breast cancer risk among Chinese women
in Stages I and II.
OR(95%CI)
Tested SNP Adjusted SNPs
No of
cases
No of
controls Frequencya Heter Homo Per allele P for trend
rs4784227 None 6,346 3,921 0.28/0.24 1.24(1.14–1.35) 1.50(1.28–1.77) 1.23(1.16–1.31) 2.1610210
rs8051542 None 6,158 3,658 0.20/0.18 1.10(1.01–1.21) 1.36(1.09–1.69) 1.13(1.05–1.21) 0.002
rs12443621 None 2,954 2,997 0.57/0.57 0.99(0.86–1.14) 1.02(0.88–1.18) 1.01(0.94–1.09) 0.78
rs3803662 None 6,345 3,795 0.68/0.65 1.26(1.10–1.44) 1.34(1.17–1.53) 1.12(1.06–1.19) 1.761024
rs4784227 rs8051542 6,082 3,614 0.28/0.24 1.27(1.14–1.40) 1.57(1.29–1.91) 1.26(1.16–1.37) 9.561028
rs4784227 rs12443621 2,920 2,961 0.29/0.24 1.32(1.18–1.47) 1.63(1.32–2.01) 1.29(1.19–1.41) 3.161029
rs4784227 rs3803662 6,221 3,749 0.28/0.25 1.20(1.10–1.32) 1.41(1.19–1.68) 1.20(1.11–1.28) 7.061027
rs4784227 all 3 SNPs 2,702 2,646 0.29/0.24 1.31(1.14–1.50) 1.60(1.23–2.08) 1.28(1.15–1.44) 1.661025
rs8051542 rs4784227 6,082 3,614 0.20/0.18 0.93(0.84–1.04) 0.97(0.76–1.25) 0.95(0.87–1.05) 0.33
rs12443621 rs4784227 2,920 2,961 0.57/0.57 0.92(0.80–1.07) 0.89(0.77–1.04) 0.95(0.88–1.02) 0.16
rs3803662 rs4784227 6,221 3,749 0.68/0.65 1.17(1.03–1.35) 1.17(1.01–1.35) 1.05(0.99–1.13) 0.12
a Risk allele frequency in cases/controls. Risk/reference alleles (based on forward strand) are T/C for rs8051542 and rs4784227 and A/G for rs12443621 and rs3803662.
doi:10.1371/journal.pgen.1001002.t004
Table 5. Association of rs4784227 and the three previously-reported SNPs at 16q12with breast cancer risk among European
American women.
Tested SNP a Study SNPs Adjusted No of cases No of controlsFrequencyb OR (95% CI) P for trend
rs4784227 CGEMS None 1145 1142 0.29/0.25 1.17(1.03–1.34) 0.016
NBHS None 1357 1148 0.28/0.25 1.21(1.07–1.37) 0.003
rs3803662 CGEMS None 1145 1142 0.3/0.27 1.13(0.99–1.28) 0.06
NBHS None 1615 1467 0.31/0.27 1.22(1.09–1.36) 4.061024
rs8051542 NBHS None 1587 1439 0.46/0.44 1.07(0.97–1.19) 0.18
rs12443621 CGEMS None 1145 1142 0.50/0.49 1.02(0.91–1.15) 0.70
rs4784227 NBHS rs8051542 1263 1080 0.28/0.25 1.22(1.06–1.40) 0.007
rs4784227 CGEMS rs12443621 1145 1142 0.29/0.25 1.25(1.06–1.47) 0.007
rs4784227 Both rs3803662 2431 2243 0.29/0.25 1.22(0.94–1.59) 0.13
rs8051542 NBHS rs4784227 1263 1080 0.45/0.44 0.98(0.86–1.11) 0.74
rs12443621 CGEMS rs4784227 1145 1142 0.50/0.49 0.91(0.79–1.05) 0.19
rs3803662 Both rs4784227 2431 2243 0.31/0.27 0.97(0.75–1.25) 0.82
a In CGEMS, data on rs8051542 was not available, and In NBHS data on for rs12443621 was not available.
b Risk allele frequency in cases/controls. Risk/reference alleles (based on forward strand) are T/C for rs8051542 and rs4784227 and A/G for rs12443621 and rs3803662.
doi:10.1371/journal.pgen.1001002.t005
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intrinsic repressor activities, suggesting that rs4784227 may affect
its underlying gene LOC643714 or its neighborhood gene
expression and thus affect breast cancer risk. The rs4784227-
associated repressing activity could be the result of differential
binding affinity of transcription machinery to the rs4784227-
containing DNA sequences. We examined this hypothesis by
conducting electrophoretic mobility shift assays and confirmed
that the risk T allele of rs4784227 significantly alter DNA-nuclear
protein(s) interactions. Thus, it is possible that inhibitory nuclear
protein(s) selectively bind to the risk allele T to repress
transcription. A database search (http://www.cbrc.jp/research/
db/TFSEARCH.html) for transcription factor binding sites
showed that the sequence at the rs4784227 site has a high degree
of similarity with several consensus elements recognized by
transcription factors, of which HNF-3b and C/EBP prefer to
bind DNA fragments with the risk T allele of this SNP site.
However, these putative transcription factors or their associated
proteins have not been confirmed to be involved in the regulation
of LOC643714 or its nearby genes.
In summary, through a GWA study we have identified and
confirmed rs4784227 as a genetic risk variant for breast cancer. In
vitro experiments showed a functional significance of this SNP that
may explain the association of breast cancer with other SNPs
identified at locus 16q12.1. This study demonstrates the
importance of conducting genetic association studies in popula-
tions with different LD structures to identify causal genetic variants
for breast cancer and other complex diseases.
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